PLANTATION, Fla.–(BUSINESS WIRE)–Oncology Analytics, a comprehensive oncology benefits management and analytics company serving health plans, providers and patients in the United States and Puerto Rico, announced today that its Board of Directors has appointed Rick Dean as Chief Executive Officer effective immediately. Mr. Dean will join the Board of Directors. Dr. Marc Fishman, the founder and former CEO of the company, will assume the role of Executive Chairman.
Mr. Dean brings more than two decades of experience to Oncology Analytics, including successfully leading and growing innovative healthcare companies through various stages of maturation. “Rick is an entrepreneurial and innovative leader with experience across both large and small healthcare companies. His experience provides a unique blend of operational excellence, analytical expertise in the healthcare industry, innovative thinking and accelerated growth strategies,” said Dr. Marc Fishman, Executive Chairman of Oncology Analytics.
Mr. Dean comes to Oncology Analytics from Optum, the healthcare services arm of UnitedHealth Group (NYSE:UNH). At Optum, Mr. Dean was a founding member of Optum Ventures, a venture capital fund focused on digital health innovation. Prior to Optum Ventures, he was Senior Vice President for Optum Analytics responsible for global sales and growth. Mr. Dean came to Optum from Humedica, a transformative population health and analytics company, where he was the company’s Chief Growth Officer. Humedica was acquired by UnitedHealth Group in 2013. Prior to Humedica, Mr. Dean was senior vice president of North American sales for Sentillion, a highly successful venture backed healthcare company that was acquired by Microsoft in 2010. Mr. Dean is a past Board member of AMGA Analytics, the informatics subsidiary of the American Medical Group Association.
“We are extremely pleased that Rick is assuming the leadership role at Oncology Analytics. After a thorough search, we felt that Rick’s background and demonstrated success as a growth leader and visionary was the right fit for Oncology Analytics. In the United States, where cancer drug spending exceeds $38 billion annually, the need for innovative analytics and oncology benefit management services is extremely important to ensure that patients, health plans and providers are utilizing evidence-based treatments that are efficacious and affordable. Rick’s ability to understand complex problems and create strategic solutions will help Oncology Analytics continue to lead the way in oncology benefit management,” said Nick Rosa, CEO of Sandbox Industries, who represents BlueCross BlueShield Venture Partners (“BCBSVP”) on the Oncology Analytics Board. BCBSVP is a key investor in Oncology Analytics.
About Oncology Analytics, Inc.:
Oncology Analytics, Inc. is a comprehensive oncology benefits management and analytics company serving health plans, providers and over 2 million health plan members in the U.S. and Puerto Rico. Oncology Analytics has continued its mission of using evidence-based medicine and analytics to drive better treatment options for cancer care at reduced costs through its proprietary MATIS software platform. Using a patient-focused approach, Oncology Analytics’ clinical team of board-certified hematologists/oncologists, oncology RNs, and board-certified oncology pharmacists ensure high quality care for our clients and their members. For more information, please visit www.oncologyanalytics.com.
About BlueCross BlueShield Venture Partners:
BlueCross BlueShield Venture Partners, L.P. is a corporate venture fund licensed by the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. The fund invests in promising emerging companies of strategic relevance to Blue Cross and Blue Shield Plans. Sandbox Industries is the exclusive provider of investment management services to BlueCross BlueShield Venture Partners. For more information, visit www.bcbsvp.com.